Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Down 81.5% in March

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a significant drop in short interest in the month of March. As of March 13th, there was short interest totaling 899,445 shares, a drop of 81.5% from the February 26th total of 4,865,346 shares. Based on an average daily volume of 1,570,480 shares, the days-to-cover ratio is currently 0.6 days. Approximately 22.2% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Avalon GloboCare in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Avalon GloboCare presently has a consensus rating of “Sell”.

Avalon GloboCare Price Performance

Shares of NASDAQ:ALBT opened at $0.59 on Thursday. Avalon GloboCare has a one year low of $0.42 and a one year high of $5.99. The company has a market cap of $2.53 million, a price-to-earnings ratio of -0.17 and a beta of -0.23. The firm has a 50 day simple moving average of $0.79 and a 200 day simple moving average of $1.48.

About Avalon GloboCare

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.